Jonathan Lim, Erasca CEO (Arch Venture Partners)

Nas­daq rings in Jonathan Lim's next can­cer play, Pfiz­er-backed start­up and Har­vard spin­out with col­lec­tive $534M raise un­der their belts

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

IPOs are boom­ing in 2021, and com­pa­nies are go­ing pub­lic ear­li­er than ever.

About 45% of IPOs of­fered in the first half of the year were for com­pa­nies that were still in pre­clin­i­cal and dis­cov­ery stages. That’s a big change for the 66 bio­phar­ma ther­a­peu­tics and plat­form com­pa­nies who com­plet­ed their IPO in the first half of the year, rais­ing $9.3 bil­lion in to­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA